Ligand Pharmaceuticals Incorporated
LGND News Today: Stay Updated with the Latest Ligand Pharmaceuticals Incorporated News in Real Time
Find LGND news now at Meyka AI. Stay informed with the latest Ligand Pharmaceuticals Incorporated stocks updates, including price news, market analysis, and expert insights.
Tigress Maintains Strong Buy on Mastercard Incorporated (MA) March 13 2026
MA analyst rating: Tigress maintains Strong Buy and raises price target to $735 on March 13, 2026
JPY 1151.00 on 14 Mar 2026 for Tecnos Japan 3666.T (JPX): Oversold bounce set-up, watch 50-day pivot
3666.T stock at JPY 1151.00 pre-market 14 Mar 2026; oversold bounce setup with JPY 1,365.00 12-month target
US Tariffs Today, March 13: Section 301 Probe Targets Switzerland, EU
Switzerland faces fresh US trade risk as Section 301 probes open. Key dates, sectors, and investor actions as Donald Trump tariffs advance toward July decisions.
FTSE 100 Live: Stocks Slip as US Relaxes Sanctions on Russian Oil
Global markets reacted cautiously after the United States signaled a relaxation of some restrictions on Russian oil trade. The move affected energy prices and investor sentiment across Europe. As a result, the FTSE 100 index in London moved slightly lower during the latest trading session. Market participants are closely watching how changes in oil policy…
Cantor Fitzgerald Keeps Overweight on Agios Pharmaceuticals, Inc. (AGIO) Mar 2026
Cantor Fitzgerald keeps Overweight on Agios (AGIO) March 12, 2026; we analyze the AGIO analyst rating and implications
-5.71% intraday: NWRN.SW Newron (SIX) Mar 2026 earnings risk may spark moves
NWRN.SW stock falls to CHF16.50 intraday. Earnings on 24 Mar may drive volatility and upside potential per Meyka AI forecast.
Singapore Challenges US Trade Surplus Figures Ahead of Potential Tariffs
Trade tensions between Singapore and the United States have taken a new turn. In early March 2026, Singapore publicly disputed US claims that it ran a large trade surplus with the United States. Singapore says the official American figures are simply wrong, and this disagreement is sparking fresh concerns about possible tariffs and broader impacts…
Down 7.16% pre-market on SIX: Santhera Pharmaceuticals (SANN.SW) CHF15.82 signals volatility and catalyst risk
Pre-market: SANN.SW stock down 7.16% to CHF15.82 on 13 Mar 2026; outlook, Meyka AI forecast and risks
ALNA Allena Pharmaceuticals (NASDAQ) pre-market Mar 2026: $0.08, most active pick
ALNA stock pre-market update: trading at USD 0.075 with heavy volume and analyst-grade outlook from Meyka AI